Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04406415 · ClinicalTrials.gov registry record · Phase 1
Oral Nafamostat in Healthy Volunteers (NAF-101)
A Phase 1 study, sponsored by Ensysce Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT04406415 is a Phase 1 study that has completed, run by Ensysce Biosciences. The registered enrollment target is 17 participants.
The verdict
NCT04406415, a Phase 1 study, has completed, sponsored by Ensysce Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled Multiple Ascending Dose (MAD) study to evaluate the safety, tolerability and pharmacokinetics of oral nafamostat solution administered t.i.d.. for up to 5 days in healthy volunteer adult subjects
Interventions
- DRUG Placebo
- DRUG Nafamostat Mesilate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-09-21 |
| Est. Completion | 2021-05-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04406415
The ClinicalTrials.gov registry entry for NCT04406415 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ensysce Biosciences, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04406415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04406415 about?
NCT04406415 is a clinical study titled "Oral Nafamostat in Healthy Volunteers (NAF-101)". This is a randomized, double-blind, placebo-controlled Multiple Ascending Dose (MAD) study to evaluate the safety, tolerability and pharmacokinetics of oral nafamostat solution administered t.i.d.. for up to 5 days in healthy volunteer adult subjects
What is the current status of trial NCT04406415?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2020-09-21. Estimated completion is 2021-05-14.
What interventions are being tested in trial NCT04406415?
The interventions under investigation include: Placebo (DRUG), Nafamostat Mesilate (DRUG).
Who is sponsoring clinical trial NCT04406415?
This trial is sponsored by Ensysce Biosciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.